- Recruiting
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
Updated: Sep 24, 2022
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of the study is to assess the safety and tolerability, and identify the recommended dose of REGN5458 for the expansion portion in combination with each one of the following cancer treatments:
Daratumumab plus dexamethasone (Dd: Cohort 1)
Carfilzomib plus dexamethasone (Kd: Cohort 2)
Lenalidomide plus dexamethasone (Rd: Cohort 3)
Bortezomib plus dexamethasone Vd: (Cohort 4)
Sponsor
ClinicalTrials.gov Identifier: NCT05137054
Official Title: Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma
First Posted: November 30, 2021
Click here for details on ClinicalTrials.gov
Linvoseltamab (Code C158504)
Anti-BCMA x Anti-CD3 BiTE REGN5458
Anti-BCMA/CD3 BiTE Antibody REGN5458
Bispecific BCMA x CD3 T-cell Engaging Antibody REGN5458
BiTE Antibody REGN5458
Linvoseltamab
LINVOSELTAMAB
REGN 5458
REGN-5458
REGN5458
Drug: REGN5458
Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
Locations
Europe
Spain
Related Posts
NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)
NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM